DD128332A5 - Verfahren zur herstellung von verbindungen mit antidepressiver wirkung - Google Patents

Verfahren zur herstellung von verbindungen mit antidepressiver wirkung

Info

Publication number
DD128332A5
DD128332A5 DD7600191893A DD19189376A DD128332A5 DD 128332 A5 DD128332 A5 DD 128332A5 DD 7600191893 A DD7600191893 A DD 7600191893A DD 19189376 A DD19189376 A DD 19189376A DD 128332 A5 DD128332 A5 DD 128332A5
Authority
DD
German Democratic Republic
Prior art keywords
preparing compounds
antidepressive effect
antidepressive
effect
preparing
Prior art date
Application number
DD7600191893A
Other languages
German (de)
English (en)
Inventor
Hendricus B A Welle
Volkert Claassen
Original Assignee
Philips Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philips Nv filed Critical Philips Nv
Publication of DD128332A5 publication Critical patent/DD128332A5/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/08—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DD7600191893A 1975-03-20 1976-03-17 Verfahren zur herstellung von verbindungen mit antidepressiver wirkung DD128332A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7503310A NL7503310A (nl) 1975-03-20 1975-03-20 Verbindingen met antidepressieve werking.

Publications (1)

Publication Number Publication Date
DD128332A5 true DD128332A5 (de) 1977-11-09

Family

ID=19823424

Family Applications (1)

Application Number Title Priority Date Filing Date
DD7600191893A DD128332A5 (de) 1975-03-20 1976-03-17 Verfahren zur herstellung von verbindungen mit antidepressiver wirkung

Country Status (27)

Country Link
US (1) US4085225A (enExample)
JP (1) JPS6026776B2 (enExample)
AR (2) AR211011A1 (enExample)
AT (1) AT340895B (enExample)
AU (1) AU505358B2 (enExample)
BE (1) BE839744A (enExample)
CA (1) CA1076142A (enExample)
CH (4) CH626057A5 (enExample)
DD (1) DD128332A5 (enExample)
DE (1) DE2610886A1 (enExample)
DK (1) DK144942C (enExample)
ES (1) ES446192A1 (enExample)
FI (1) FI61875C (enExample)
FR (1) FR2304336A1 (enExample)
GB (1) GB1535226A (enExample)
GR (1) GR60052B (enExample)
HU (1) HU171030B (enExample)
IE (1) IE43768B1 (enExample)
IL (1) IL49238A (enExample)
IT (1) IT1063064B (enExample)
MX (1) MX9203723A (enExample)
NL (1) NL7503310A (enExample)
PL (3) PL100052B1 (enExample)
SE (1) SE410312B (enExample)
SU (3) SU635867A3 (enExample)
YU (1) YU39345B (enExample)
ZA (1) ZA761434B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1110460B (it) * 1977-03-02 1985-12-23 Ciba Geigy Ag Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
US5665756A (en) * 1994-08-03 1997-09-09 Hoechst Marion Roussel, Inc. Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
EP0759299B1 (en) * 1995-08-16 2000-04-26 Eli Lilly And Company Potentiation of serotonin response
IN182588B (enExample) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
IN186677B (enExample) 1999-11-12 2001-10-20 Sun Pharmaceutical Ind Ltd
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
US7256191B2 (en) * 2000-04-24 2007-08-14 Aryx Therapeutics Materials and methods for the treatment of depression
CA2405025A1 (en) 2000-04-24 2001-11-01 Aryx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
AU2002342045C1 (en) * 2001-10-12 2009-07-30 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin Vla antagonists
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
MXPA06002789A (es) 2003-09-12 2006-06-14 Pfizer Combinaciones que comprenden ligandos alfa-2-delta.
EP1689721B1 (en) * 2003-11-26 2010-07-14 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
EP1745180A1 (en) * 2004-04-29 2007-01-24 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006102283A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
PE20061298A1 (es) 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
WO2006116170A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
PE20061319A1 (es) * 2005-04-22 2006-12-28 Wyeth Corp Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2-3-dihidro-1-benzofurano-2-il]metil}amina
CA2605554A1 (en) 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
AU2006269231A1 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
PL1910346T3 (pl) * 2005-07-19 2019-09-30 Azevan Pharmaceuticals, Inc. Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny
JP2009502807A (ja) * 2005-07-22 2009-01-29 ミリアド ジェネティクス， インコーポレイテッド 薬剤含有率の高い製剤および投与量形態
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
TW200806300A (en) * 2006-03-24 2008-02-01 Wyeth Corp New therapeutic combinations for the treatment of depression
JP4615470B2 (ja) * 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
EP2125017A2 (en) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation of neurogenesis with use of modafinil
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MX2012004753A (es) 2009-10-23 2012-09-07 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina.
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
RU2623209C9 (ru) 2010-07-01 2018-01-22 Азеван Фармасьютикалз, Инк. Способы лечения посттравматического стрессового расстройства
EP2685966A1 (en) 2011-03-17 2014-01-22 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
PT2981518T (pt) 2013-04-03 2021-06-04 Zcl Chemicals Ltd Um processo melhorado para a preparação de maleato de fluvoxamina
US10124006B2 (en) 2014-02-07 2018-11-13 MTA Tämogatott Kutatócsoportok Irodája Use of Sigma-1 receptor agonist compounds
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
RS63296B1 (sr) 2016-03-10 2022-07-29 Janssen Pharmaceutica Nv Metode lečenja depresije korišćenjem antagonista receptora oreksin-2
US12239125B2 (en) 2016-11-24 2025-03-04 SigmaDrugs Kutató Korlátolt Felelsség Társaság Compositions for organ preservation
MX2020002762A (es) 2017-09-15 2020-09-17 Azevan Pharmaceuticals Inc Composiciones y métodos para tratar una lesión cerebral.
JP7739256B2 (ja) 2019-07-19 2025-09-16 バイオエクセル セラピューティクス，インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692835A (en) * 1967-04-05 1972-09-19 Jan Van Dijk Pharmacologically active amino-ethyl oximes

Also Published As

Publication number Publication date
PL100052B1 (pl) 1978-08-31
JPS6026776B2 (ja) 1985-06-25
SE410312B (sv) 1979-10-08
SU620206A3 (ru) 1978-08-15
NL7503310A (nl) 1976-09-22
CH629477A5 (de) 1982-04-30
YU39345B (en) 1984-10-31
CH626057A5 (enExample) 1981-10-30
DK115976A (da) 1976-09-21
FI61875C (fi) 1982-10-11
ATA195476A (de) 1977-05-15
DK144942B (da) 1982-07-12
IL49238A (en) 1978-08-31
PL101951B1 (pl) 1979-02-28
SE7603341L (sv) 1976-09-21
CA1076142A (en) 1980-04-22
CH629761A5 (de) 1982-05-14
AT340895B (de) 1978-01-10
AR211153A1 (es) 1977-10-31
IT1063064B (it) 1985-02-11
IE43768L (en) 1976-09-20
ES446192A1 (es) 1977-10-01
SU635867A3 (ru) 1978-11-30
JPS51125345A (en) 1976-11-01
US4085225A (en) 1978-04-18
DE2610886C2 (enExample) 1987-09-24
GR60052B (en) 1978-04-04
MX9203723A (es) 1992-07-01
PL100614B1 (pl) 1978-10-31
BE839744A (fr) 1976-09-20
DE2610886A1 (de) 1976-10-07
GB1535226A (en) 1978-12-13
FI61875B (fi) 1982-06-30
FI760699A7 (enExample) 1976-09-21
FR2304336B1 (enExample) 1979-09-28
AU1214776A (en) 1977-09-22
AR211011A1 (es) 1977-10-14
AU505358B2 (en) 1979-11-15
CH629184A5 (de) 1982-04-15
IE43768B1 (en) 1981-05-20
HU171030B (hu) 1977-10-28
SU645559A3 (ru) 1979-01-30
FR2304336A1 (fr) 1976-10-15
YU71476A (en) 1982-10-31
DK144942C (da) 1982-12-06
ZA761434B (en) 1977-10-26
IL49238A0 (en) 1976-05-31

Similar Documents

Publication Publication Date Title
DD128332A5 (de) Verfahren zur herstellung von verbindungen mit antidepressiver wirkung
DD130857A5 (de) Verfahren zur herstellung von n-phosphonomethylglycintriestern
DD131931A5 (de) Verfahren zur herstellung von spiro-hydantoin-verbindungen
DD129330A5 (de) Verfahren zur herstellung von antitumorsubstanzen
DD127928A5 (de) Verfahren zur herstellung heterocyclischer verbindungen
DD131649A5 (de) Verfahren zur herstellung von n-(perfluoracyl)-n-phosphono-methyl-glycin-verbindungen
DD131858A5 (de) Verfahren zur herstellung von 3-chlorcephemverbindungen
DD130036A5 (de) Verfahren zur herstellung von optisch aktiven 11-desoxy-16-aryloxy-omega-tetranorprostaglandinen
DD129326A5 (de) Verfahren zur herstellung von 1,4-diphenyl-3-pyrazolin-5-onen
AT341668B (de) Verfahren zur herstellung von 7-aminocephemverbindungen
AT342191B (de) Verfahren zur herstellung von arzneimittelkombinationen
AT333305B (de) Verfahren zur herstellung von phosphonothioureidoverbindungen
DD128330A5 (de) Verfahren zur herstellung von verbindungen mit antidepressiver wirkung
DD131562A5 (de) Verfahren zur herstellung von 5-pregnen-derivaten
DD122961A5 (de) Verfahren zur herstellung von diphenylaether-derivaten
AT352914B (de) Verfahren zur herstellung von polyen- verbindungen
DD122976A5 (de) Verfahren zur herstellung von pyridoepoxyaethanen
DD122964A5 (de) Verfahren zur herstellung von prostensaeurederivaten
DD128329A5 (de) Verfahren zur herstellung von verbindungen mit antidepressiver wirkung
AT339268B (de) Verfahren zur herstellung von acetoxybutanolen
DD133327A5 (de) Verfahren zur herstellung von organischen verbindungen
AT350199B (de) Verfahren zur herstellung von 17-monoestern von 17alfa,21-dihydroxysteroiden
DD133147A5 (de) Verfahren zur herstellung antihelmintischer verbindungen
AT338775B (de) Verfahren zur herstellung von 4-oxa-5-hydroxypolycycloalken-3-onen
DD128709A5 (de) Verfahren zur herstellung von dekahydrochinolinderivaten